Myeloproliferative neoplasms (MPN) are driven primarily by somatically acquired mutations in JAK2, CALR or MPL. 1 In addition, evidence from epidemiological and family studies indicates that common, low-penetrance genetic variants present in the general population contribute to the risk of developing MPN. 2 Some of these variants have been identified, for example, the JAK2 46/1 haplotype is strongly associated with the acquisition of JAK2 mutations [3] [4] [5] and also predisposes to JAK2-unmutated disease, along with variation at TERT, MECOM and HBS1L/MYB. 6 Furthermore, variation at HBS1L/MYB contributes to MPN phenotype, specifically the A allele of rs9376092 is associated with essential thrombocythemia (ET) as opposed to polycythemia vera in JAK2 V617F-positive MPN, whereas in JAK2 V617F-negative ET and primary myelofibrosis it has a stronger effect in cases with somatic CALR or MPL mutations compared with those that are triple negative. 6 All CALR mutations are indels located in the last exon of the gene that generate a +1 frameshift and encode a protein with an aberrant carboxyl terminus. 7, 8 The great majority (80-85%) are classed as either type 1 (52 bp deletion) or type 2 (5 bp insertion) and emerging evidence suggests that these subtypes have different biological features 9 associated with distinct clinical outcomes. 10, 11 Recently it has been suggested that there is a constitutional allelic imbalance at the CALR locus associated with somatic CALR mutations, which may indicate a genetic influence on the probability of acquiring a CALR mutation and/or the probability of such a mutation leading to the development of an MPN. 12 Harutyunyan and colleagues analysed 162 CALR-mutated cases that were heterozygous (T/G) for rs1049481, a common SNP located 54 bp downstream of the CALR stop codon. If there was no allelic imbalance, CALR mutations would be expected to be distributed 50:50 between the G and T alleles, but Harutyunyan et al. observed that CALR mutations occurred more frequently on the T allele (100 on the T allele versus 62 on the G allele; P = 0.0028). Furthermore, they found that the effect was most pronounced for cases with type 2 CALR mutations (5 bp insertion) but was also discernible for cases with type 1 mutations (52 bp deletion). No difference in rs1049481 genotype was seen for cases with other CALR frameshift mutations and no difference in rs1049481 genotype was seen on comparison of cases and controls, suggesting that the association is much weaker than that between JAK2 V617F and the 46/1 haplotype.
We sought to determine whether the observed allelic imbalance was reproducible in an independent group of patients. Cases were recruited from the UK, having been referred initially for routine molecular diagnostic evaluation. Approval was obtained by the relevant internal review boards or ethics committees and informed consent was provided according to the Declaration of Helsinki. We identified a total of 334 CALR-mutated MPN cases, as determined by fragment and/or sequence analysis. 7, 13 Of these, 166 were heterozygous for rs1049481, 75 were homozygous for GG and 93 were homozygous for TT. The breakdown of these cases by CALR mutation type is given in Table 1 .
To determine which allele the CALR mutation had arisen on in rs1049481 heterozygous cases, we performed allele-specific PCR using a modified version of the assay described previously. 12 An unlabelled forward primer (5′-GGCAAGGCCCTGAGGTGT-3′) that binds to the intron upstream of the CALR mutation cluster was used in combination with specific labelled reverse primers that bind either to the G-or T-allelic variants of rs1049481. We used a T reverse primer that was six nucleotides longer than the G allele primer (5′-TTTTTTAGACATTATTTGGCGCGGCA-3′ and 5′-AGACATTATTTGGCGCGGCC-3′, respectively) to facilitate the analysis. Cycling conditions were 95°C for 10 min, 30 cycles of 95°C for 1 min, 65°C for 1 min, 72°C for 1 min, followed by 72°C for 30 min. Products were diluted between 1/10 and 1/100 in sterile water and sized on a 3130 Genomic Analyser (Life Technologies, Paisley, UK). Results were analysed using GeneMarker software version 1.85 (SoftGenetics, State College, PA, USA) on the blue (FAM) channel. Products with peak heights between 1000 and 6000 relative fluorescent units were analysed.
We focused initially on the 166 cases that were heterozygous for rs1049481. In contrast to Harutyunyan et al., we found an excess of CALR mutations on the G allele, although the difference is not significant (80 on the T allele versus 89 on the G allele; P = 0.641; one proportion Z-test, two-tailed). Type 1 mutations were found more frequently on the G allele, whereas type 2 mutations were more frequent on the T allele, but again neither of these differences achieved statistical significance. Similarly, no significant differences or even suggestive trends emerged when we considered all CALR-mutated cases in our study (n = 334), either as a group or broken down by CALR mutation subtype. Overall, therefore, our data do not support the notion of a constitutional allelic imbalance associated with CALR mutations. Telomere erosion and fusion have an important role in the pathology of many common human malignancies including chronic lymphocytic leukemia (CLL). 1, 2 Previous studies in CLL have shown that short telomeres defined on the basis of the median value or receiver operating characteristic analysis are associated with unmutated IGHV genes, poor-risk genomic abnormalities, genomic complexity and high expression of CD38, CD49d and ZAP70 whereas long telomeres are associated with increasing IGHV mutational load, isolated deletion of 13q and low CD49d expression. In addition, in predominantly diagnostic or mixed patient cohorts, telomere length (TL) predicts time to first treatment and/or overall survival (OS) in multivariate analyses of models incorporating established biomarkers. [3] [4] [5] [6] [7] However uncertainties about the most clinically relevant measure of TL, the optimal choice of assay, the need for assay standardisation and the lack of published data on the prognostic value of TL in patients entered into randomised trials have hindered the implementation of TL measurement into routine clinical practice.
We have attempted to address these issues by measuring TL using monochrome multiplex Q-PCR (MMQ-PCR) in 384 patients at randomisation into the UK LRF CLL4 phase 3 chemotherapy trial ( Supplementary Table S1 ), of whom 111 samples were also screened by single telomere length analysis (STELA). TL and established biomarkers were measured as previously described. [8] [9] [10] [11] [12] [13] The mean TL assessed by MMQ-PCR in 384 cases was 3.57 TLU (TL units, range 0.61-19.05). For 111 patients randomised to the fludarabine plus cyclophosphamide arm analysed by both MMQ-PCR and STELA, we showed an excellent correlation between these two TL measurements (Spearman correlation 0.80; Supplementary Fig. S1 ), permitting the calibration of the mean TLU to a mean absolute TL of 3.39 kb (range 1.93-11.06 kb, median 2.92 kb (inter quartile range: 2.58, 3.60)) for our cohort. All subsequent analyses were based on data derived from MMQ-PCR expressed in kb rather than TLU. TL was found to be significantly associated with IGHV mutation status, ZAP70 and CD38 expression, serum beta-2 microglobulin, TP53 abnormality, 11q deletion, genomic complexity, ATM and SF3B1 mutation but not trisomy 12 or NOTCH1 mutation ( Supplementary Table S2 ).
Increasing TL, entered as a continuous variable, was associated with a significant reduction in risk of a progression free survival (PFS) event (hazard ratio (HR) = 0.89, 95% confidence interval (CI): 0.85-0.93, Po 0.001) and longer OS (HR = 0.84, 95% CI: 0.80-0.89, P o0.001; Supplementary Table S3 ). To determine a single TL cutoff value with maximum prognostic power, we employed recursive partitioning and identified the 75th and 80th percentile for PFS (HR: 2.42, P o0.001) and OS (HR: 3.17, P o0.001), respectively ( Supplementary Fig. S2 ), demonstrating that identifying cases with the longest telomeres is key to maximising the prognostic value of these data. We then performed Kaplan-Meier analysis and generated a categorical variable with three groups for TL-short (o 50 percentile), intermediate (50-75 percentile) and long (475 percentile; Figure 1 and Supplementary Fig. S3 ).
